Contact
searchSearch
HMP Global
Ryotaro Ishii, MD, PhD, Discusses Lowering the Diagnosis Criteria for Chronic Migraine
06/29/2021
Chronic migraine should be distinguished by 8 headache days per month based on migraine burden, according to new research presented at the American Headache Society Virtual Scientific Meeting.
Chronic migraine should be distinguished by 8 headache days per month based on migraine burden, according to new research presented at the American Headache Society Virtual Scientific Meeting.
Chronic migraine should be...
06/29/2021
Neurology
Videos
The Impact of Gender on Headache Treatment
06/14/2021
In this video, Anna Pace, MD, Icahn School of Medicine at Mount Sinai, New York, New York, discusses her recent presentation at the American Headache Society Virtual Annual Scientific Meeting, “Does Gender Impact the Presentation of Headache...
In this video, Anna Pace, MD, Icahn School of Medicine at Mount Sinai, New York, New York, discusses her recent presentation at the American Headache Society Virtual Annual Scientific Meeting, “Does Gender Impact the Presentation of Headache...
In this video, Anna Pace, MD,...
06/14/2021
Neurology
Conference Coverage
Hesitancy in Migraine Care Consultation Related to Lifestyle Factors
06/07/2021
Sociodemographic and lifestyle factors can limit the ability and willingness of individuals suffering from migraine to access and receive care.
Sociodemographic and lifestyle factors can limit the ability and willingness of individuals suffering from migraine to access and receive care.
Sociodemographic and lifestyle...
06/07/2021
Neurology
Conference Coverage
Ubrogepant Safe for Treatment of Perimenstrual Migraine
06/07/2021
Ubrogepant is a safe and effective treatment option for patients with perimenstrual migraine, according to recent findings presented at the American Headache Society 2021 Virtual Annual Scientific Meeting.
Ubrogepant is a safe and effective treatment option for patients with perimenstrual migraine, according to recent findings presented at the American Headache Society 2021 Virtual Annual Scientific Meeting.
Ubrogepant is a safe and...
06/07/2021
Neurology
Matthew Robbins, MD: The State of Headache Medicine During COVID-19
Podcasts
Matthew Robbins, MD: The State of Headache Medicine During COVID-19
09/10/2020
In this podcast, Dr. Robbins discusses how the pandemic has impacted headache medicine, key areas of future research, and what neurologists should keep in mind. He recently gave a talk about this topic at the American Headache Society Annual...
In this podcast, Dr. Robbins discusses how the pandemic has impacted headache medicine, key areas of future research, and what neurologists should keep in mind. He recently gave a talk about this topic at the American Headache Society Annual...
In this podcast, Dr. Robbins...
09/10/2020
Neurology
Kathleen Digre, MD: The Role of Eye Pain and Photophobia in Migraine, Dry Eyes, and More
Podcasts
Kathleen Digre, MD: The Role of Eye Pain and Photophobia in Migraine, Dry Eyes, and More
07/10/2020
In this podcast, Dr Digre discusses the association of photophobia and eye pain with migraine, dry eyes, and related conditions, as well as common pitfalls in the management and treatment of photophobia and eye pain.
In this podcast, Dr Digre discusses the association of photophobia and eye pain with migraine, dry eyes, and related conditions, as well as common pitfalls in the management and treatment of photophobia and eye pain.
In this podcast, Dr Digre...
07/10/2020
Neurology

Migraine CME Series

News

Conference Coverage
Hesitancy in Migraine Care Consultation Related to Lifestyle Factors
06/07/2021
Sociodemographic and lifestyle factors can limit the ability and willingness of individuals suffering from migraine to access and receive care.
Sociodemographic and lifestyle factors can limit the ability and willingness of individuals suffering from migraine to access and receive care.
Sociodemographic and lifestyle...
06/07/2021
Neurology
Conference Coverage
Ubrogepant Safe for Treatment of Perimenstrual Migraine
06/07/2021
Ubrogepant is a safe and effective treatment option for patients with perimenstrual migraine, according to recent findings presented at the American Headache Society 2021 Virtual Annual Scientific Meeting.
Ubrogepant is a safe and effective treatment option for patients with perimenstrual migraine, according to recent findings presented at the American Headache Society 2021 Virtual Annual Scientific Meeting.
Ubrogepant is a safe and...
06/07/2021
Neurology

Alzheimer's Disease CME Series

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use